In Vitro Potentiation of Antibiotic Activities by a Catecholate Iron Chelator against Chloroquine-Resistant
Plasmodium falciparum

Bruno Pradines,1* Florence Ramiandrasoa,2 Jean Marc Rolain,1,3 Christophe Rogier,1 Joel Mosnier,1 William Daries,1 Thierry Fusai,1 Gerhard Kunesch,2 Jacques Le Bras,4 and Daniel Parzy1

Unité de Parasitologie, Institut de Médecine Tropicale du Service de Santé des Armées, Le Pharo, 13007 Marseille,1 Laboratoire de Chimie Bioorganique et Bioinorganique, CNRS URA 1384, Institut de Chimie Moléculaire d’Orsay, 91405 Orsay,2 Unité des Rickettsies, CNRS-UPRES A 6020, Faculté de Médecine, Université de la Méditerranée, 13385 Marseille,3 and Centre National de Chimiosensibilité du Paludisme, Laboratoire de Parasitologie, Hôpital Bichat-Claude Bernard, 75018 Paris,4 France

Received 2 August 2001/Returned for modification 25 September 2001/Accepted 15 October 2001

FR160, a catechol iron chelator, and tetracyclines or norfloxacin exert in vitro additive or synergistic activity against a chloroquine-resistant Plasmodium falciparum clone. FR160 shows antagonistic effects in association with macrolides, ofloxacin, and rifampin.

The emergence and spread of parasite resistance to currently used antimalarial drugs indicates that novel compounds need to be discovered and developed by identification of novel chemotherapeutic targets (18). Iron chelation therapy was considered a suitable treatment for various infectious diseases, including malaria (10). Iron is needed for catalysis of DNA synthesis and for a variety of enzymes involved in electron transport and energy metabolism. Recent experimental observations obtained in vitro (9, 25), in rodent (6) and primate (19) models, and in clinical studies (8, 15) showed antimalarial activity of desferrioxamine. However, the time window of action of desferrioxamine is relatively limited, and the antimalarial activity is slow to develop, even after continuous in vitro or in vivo exposure to desferrioxamine (4). Various iron chelators were assessed to improve the drug lipophilicity, leading to increased access of drug to intracellular parasites and to faster action (13, 14). In addition, several studies explored the possibility of improving the antimalarial efficacy of iron chelators by using them in various combinations of iron chelators with different speeds of action, stage dependences, and degrees of reversibility of effects (7, 27, 28). The in vitro activity of FR160, a catecholate siderophore derived from spermidine, was shown previously (21). Use of combinations of antimalarials that do not have the same resistance mechanisms will reduce the chance of selection because the chance of a resistant mutant surviving is the product of the per-parasite mutation rates for the individual drugs multiplied by the number of parasites in an infection that are exposed to the drugs (29).

In this study, we assessed the combined action of FR160 with antibiotics against Plasmodium falciparum.

Parasites. When required for drug assays, the chloroquine-resistant clone W2 (Indochina) was synchronized by sorbitol lysis (12). Susceptibilities to FR160 and antibiotics were determined after suspension in RPMI 1640 medium (Life Technologies, Paisley, United Kingdom) supplemented with 10% human serum (pooled from different A+ or AB sera from nonimmune donors) and buffered with 25 mM HEPES and 25 mM NaHCO3 (hematocrit of 1.5% and parasitemia of 0.5%).

Drugs. The synthesis of FR160 was previously described (21). All antibiotics were obtained from Sigma Chemical (St. Louis, Mo.). Stock solutions were prepared in methanol for FR160, tetracycline, doxycycline, minocycline, oxytetracycline, erythromycin, spiramycin, roxithromycin, and rifampin and in dimethyl sulfoxide for ofloxacin, norfloxacin, and rolitetracycline. Twofold serial dilutions were prepared in sterile distilled water or RPMI for all these drugs. Final concentrations were distributed in triplicate into Falcon 96-well flat-bottom plates (Becton Dickinson, Franklin Lakes, N.J.).

TABLE 1. In vitro activities of the iron chelator FR160 and different tetracyclines, macrolides, quinolones, and rifampin against the chloroquine-resistant clone W2

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Mean IC50 (µM)</th>
<th>95% CI a</th>
</tr>
</thead>
<tbody>
<tr>
<td>FR160</td>
<td>1.01</td>
<td>0.90–1.12</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>7.7</td>
<td>7.1–8.4</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>33.8</td>
<td>26.4–43.3</td>
</tr>
<tr>
<td>Minocycline</td>
<td>16.0</td>
<td>11.8–21.6</td>
</tr>
<tr>
<td>Oxytetracycline</td>
<td>46.0</td>
<td>44.2–47.9</td>
</tr>
<tr>
<td>Rolitetracycline</td>
<td>45.5</td>
<td>35.2–58.8</td>
</tr>
<tr>
<td>Norfloxacin</td>
<td>74.6</td>
<td>70.7–78.8</td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>112.5</td>
<td>105.1–120.3</td>
</tr>
<tr>
<td>Rifampin</td>
<td>1.3</td>
<td>1.0–1.5</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>39.4</td>
<td>27.9–55.5</td>
</tr>
<tr>
<td>Spiramycin</td>
<td>20.9b</td>
<td>18.6–23.5</td>
</tr>
<tr>
<td>Roxithromycin</td>
<td>18.6</td>
<td>14.6–23.6</td>
</tr>
</tbody>
</table>

* Corresponding author. Mailing address: IMTSSA, Unité de Parasitologie, Bd Charles Livon, Parc le Pharo, BP 46, 13998 Marseille Armées, France. Phone: 33 4 91 15 01 10. Fax: 33 4 91 15 01 64. E-mail: bruno.pradines@free.fr.

* Values are geometric means of 5 to 10 independent assays.

b Units per milliliter.
In vitro assay. The isotopic microdrug test used in this study was described previously (20). The 50% inhibitory concentration (IC₅₀), i.e., the drug concentration corresponding to 50% of the uptake of [³H]hypoxanthine by the parasites in drug-free control wells, was determined by nonlinear regression analysis of log dose-response curves. Data were analyzed after logarithmic transformation and expressed as the geometric mean IC₅₀s, and 95% confidence intervals (95% CI) were calculated.

Drugs combination. Combinations of FR160 with antibiotics were tested five independent times against the P. falciparum W2 clone. To evaluate drug interactions, isobolograms were constructed by plotting a pair of fractional IC₅₀s for each combination of FR160 and antibiotics. The fractional IC₅₀ for different antibiotics was calculated by dividing their fixed concentrations (12 to 16 concentrations) by the IC₅₀ of tested drugs alone and plotted on the horizontal axis. The corresponding FR160 fractional IC₅₀ was calculated by dividing the IC₅₀ of FR160 combined with fixed concentrations of antibiotics and plotted on the vertical axis. A curve was then constructed through the resulting pairs of fractions from the ends of both ends of both axes on the graph. Points above the straight diagonal line (corresponding to the points where there is no interaction between the drugs) are antagonistic; points below the straight diagonal line are considered synergistic (3).

Results. The intrinsic activities of FR160 and antibiotics are summarized in Table 1. Doxycycline shows clear synergy with...
FR160 (Fig. 1). Oxytetracycline, rolitetracycline, and norfloxacin show mild synergy. Minocycline and tetracycline are categorized as additive. The other antibiotics show antagonism.

**Discussion.** Our results indicate that combinations of FR160 and tetracyclines and norfloxacin have synergistic or additive effects against *P. falciparum* parasites. We previously showed that the in vitro activities of these antibiotics were inhibited by iron(III) like desferrioxamine or FR160 (21, 22). The antibiotics which show antagonistic effects with FR160 are not inhibited by iron(III). Norfloxacin shows synergy, while ofloxacin shows antagonism [norfloxacin is inhibited by iron(III), while ofloxacin activity is independent of iron]. FR160 enhances heme-catalyzed oxidation of lipid membranes (unpublished data) and may act, like iron chelators, against multiple iron-requiring proteins, such as the ribonucleotide reductase (RNR) or the dihydroorotate dehydrogenase (DHOD) (16). The formation and stability of the tyrosyl free radical of the R2 small subunit of the mammalian RNR, involved in de novo pyrimidine synthesis, depend on the presence of the iron center (1). Therefore, any compound that reduces the intracellular concentration of available iron below a certain level inhibits RNR activity by preventing the activation of the newly synthesized apo-R2 and the regeneration of the R2 iron center when apo-R2 is formed after losing iron (17). The antimalarial mechanism of action of tetracyclines is unknown. However, it seems that tetracycline exerts its action through an effect on parasite mitochondria and mitochondrial protein synthesis (11). The activity of *P. falciparum* DHOD, a particulate electron transport-linked enzyme involved in de novo pyrimidine synthesis and an iron-dependent enzyme, was depressed when

---

**FIG. 1**—Continued.
the parasite was cultured with tetracycline (24). Doxycycline reduced the levels of nucleoside 5′-triphosphates and 2′-deoxynucleoside 5′-triphosphates (30).

Since the mechanisms underlying the antimalarial actions of FR160 and tetracyclines, one can speculate about mechanism for synergy. Other potential targets of tetracyclines (e.g., apicoplast, which is a target for different antibiotics [5, 26]) and iron chelators (e.g., iron-dependent enzymes [16]) could be involved in synergistic effects.

Resistance to antimalarial drugs reinforces the idea that novel antimalarial drugs should not be used for monotherapy. Because of the relatively slow antimalarial action of antibiotics and enhanced activity after prolonged contact, they would be best administered in conjunction with a rapidly acting regimen. The properties of FR160 and the synergistic or additive effects of combined FR160 and tetracyclines, and especially doxycycline, which shows in vitro and in vivo activities (2, 23), are attractive. The evaluation of their in vivo antimalarial effects is now required.

This work was supported by the Délégation Générale pour l’Armement (contrat d’objectif 9810060), the Direction de la Recherche et de la Technologie/Services Techniques des Recherches et des Développements Technologiques (contrat 97/2509A), the Groupe de Recherche en Parasitologie 1077, and the Direction Centrale du Service de Santé des Armées.

REFERENCES